



**National
Multiple Sclerosis
Society**

March 07, 2016

Representative Dan Hawkins, Chair
House Health and Human Services Committee
Room 546-S
300 SW 10th St.
Topeka, Kansas 66612

Re: SB 341, Opponent

Dear Chair Hawkins and Committee Members:

I am writing on behalf of the National Multiple Sclerosis Society regarding SB 341, which would allow the use of step therapy protocols within KanCare plans. The National MS Society opposes the elimination of the current protection against step therapy/first fail protocols in KanCare MCO plans, without the addition of any consumer protections. The passage of SB 341 could have a negative impact on people living with multiple sclerosis. We would recommend, at the very least, instituting strong patient protections within the step therapy process.

Multiple sclerosis (MS) is a chronic, often devastating disease of the central nervous system. The disease course is unpredictable and varies from person to person. Symptoms range from numbness and tingling in the extremities, to blindness and paralysis. Multiple sclerosis (MS) is typically diagnosed between the ages of 20 and 50, when most are raising families, advancing careers and maximizing their earnings. Yet studies show that only 40% are in the workforce ten years after their diagnosis. Others must transition to part-time employment to accommodate their disease.

The initiation of treatment with an FDA-approved disease-modifying treatment (DMT) is recommended as soon as possible following a diagnosis of relapsing MS. Accessing the correct DMT slows disease progression, prevents relapse and can mean the difference between functioning and non-functioning, sight or loss of sight, bladder control or loss of bladder control and/or mobility and non-mobility in MS patients.

Step therapy protocols require that patients must try at least one medication selected by their insurer before the plan will grant coverage for the drug originally prescribed by the healthcare provider. Through this method, insurers often require a patient to try a lower-cost drug or service, before they will cover a more expensive option. Since MS drugs range from \$50,000 to \$65,000 per year, these protocols often affect people living with MS.

These practices involve a significant administrative burden to providers and can have negative consequences for patients. Furthermore, an MCO formulary simply cannot take into account the extenuating circumstances of



**National
Multiple Sclerosis
Society**

individual MS patients, particularly the nuances of the effects of complex DMTs on a particular patient. Some of the nuances that standardized step therapy/first fail protocols often fail to include, but are certainly not restricted to, include the following:

1. **Geographic location:** Some DMTs are administered via weekly transfusions that require patients to receive them in their prescribing neurologist's office. For rural MS patients that often live hours away from their neurologist, this is simply not feasible.
2. **Lifestyle:** DMTs that require in office transfusions, people who work during the day cannot comply with this requirement and maintain employment.
3. **Patient Adherence:** Some MS medications require that MS patients self-administer daily shots. Some patients feel unable to comply with shot self-administration or with shots in general, due to their needle-related fears. For patients that are unable to comply with this treatment, a neurologist must have the ability to prescribe an alternative therapy.

When patients are required to cycle through and document a "step"—or in some cases, more than one step—the process may result in substantial delays in receiving the treatment deemed appropriate by their healthcare provider. This process may affect patients' ability to immediately start treatment, or in some cases, their ability to continue to access their treatment. Prolonging ineffective treatment (and delaying appropriate treatment) may result in disease progression for patients, increased trips to the emergency room, hospital stays and time away from work.

Should the State of Kansas chose to enact new step therapy protocols within KanCare, the National MS Society would suggest the following patient protections for consideration to lessen the risks under step therapy protocols for people living with MS:

1. Establishment and disclosure of a step therapy override process that providers could request at any time, if a patient is stable, or the physician expects the treatment will be ineffective or will likely cause an adverse reaction. This override process must be convenient for providers to utilize.
2. Step therapy protocols based on appropriate clinical practice guidelines or published peer-reviewed data developed by independent experts with knowledge of the condition or conditions under consideration.
3. Limiting the use of step therapy for any prescribed drug to no longer than 60 days.
4. Prohibiting insurers from requiring patients to fail a drug more than once.

In closing, I would like to respectfully urge the committee to maintain the current prohibition on step therapy in KanCare or consider amending SB 341 to insure that robust patient protections are written into the final step therapy protocols.



**National
Multiple Sclerosis
Society**

Sincerely,

Kari Rinker, MPA
Senior Advocacy Manager
Kansas, Missouri and Nebraska
National MS Society 110 E Waterman, Ste 110
Wichita, KS 67206
316.854.0776
kari.rinker@nmss.org